Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    ATH434

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alterity Data Backs ATH434 Advancement to Phase 3 in MSA
    Alterity Data Backs ATH434 Advancement to Phase 3 in MSA

    19 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/19/3297357/0/en/alterity-therapeutics-data-presentations-support-advancement-of-ath434-into-phase-3-in-multiple-system-atrophy.html

    GLOBENEWSWIRE
    19 May 2026
    Share Share
    Alterity Therapeutics Releases Q3 FY26 Cash Flow Report
    Alterity Therapeutics Releases Q3 FY26 Cash Flow Report

    30 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/30/3284716/0/en/alterity-therapeutics-releases-appendix-4c-q3-fy26-quarterly-cash-flow-report-corporate-update.html

    GLOBENEWSWIRE
    30 Apr 2026
    Share Share
    Alterity Gets Positive FDA Feedback on ATH434 Phase 3
    Alterity Gets Positive FDA Feedback on ATH434 Phase 3

    27 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7211238

    FIRSTWORD PHARMA
    27 Apr 2026
    Share Share
    Alterity Pharma Gets Favorable FDA Input After ATH434 Phase 3
    Alterity Pharma Gets Favorable FDA Input After ATH434 Phase 3

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264513/0/en/Alterity-Therapeutics-Receives-Positive-FDA-Feedback-Following-Type-C-Meeting-on-ATH434-Phase-3-Program.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Alterity Therapeutics Releases Q2 FY26 Cash Flow Report & Updates
    Alterity Therapeutics Releases Q2 FY26 Cash Flow Report & Updates

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229461/0/en/Alterity-Therapeutics-Appendix-4C-Q2-FY26-Quarterly-Cash-Flow-Report-Corporate-Update.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share
    Alterity Issues Shareholder Letter Highlighting 2025 Progress
    Alterity Issues Shareholder Letter Highlighting 2025 Progress

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222672/0/en/Alterity-Therapeutics-Issues-Shareholder-Letter-Highlighting-2025-Progress-and-Key-Objectives-for-2026.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.